天津發展(00882.HK):天津生化擬掛牌出售天津房產及輔助配套設備
格隆匯6月30日丨天津發展(00882.HK)發佈公吿,天津生化擬透過公開掛牌出售程序出售該等房產及該等輔助配套設備。該潛在出售事項的掛牌底價為人民幣1.69億元。於本公吿日期,天津生化為該等房產及該等輔助配套設備的登記及實益擁有人。
該等房產包括位於中國天津市天津空港經濟區環河南路9號(土地使用權面積為20,999.9平方米)的工業用地,以及建於其上的疫苗廠區、研發樓及5項構築物(總建築面積為27,750.71平方米)。疫苗廠區目前已根據一份租賃協議出租予一名租户,租賃期由2022年6月1日起至2023年5月31日止,每月租金為人民幣272,707.42元。於該潛在出售事項完成後,上述租金收入將由中標者享有。該等輔助配套設備包括設於該等房產的220項疫苗相關機器及1項電子設備。
2022年,23價肺炎球菌多糖疫苗項目經國家藥品監督管理局國家藥品審評中心審評後,天津生化考慮從成本效益和經濟效益方面終止該項目,該等房產及該等輔助配套設備因而自此利用率較低。經考慮到該等房產及該等輔助配套設備具獨特性質,可進行的其他用途有限。董事會認為,該潛在出售事項將提高集團資產的運營效率、降低運營成本及優化集團資產結構。董事會相信,該潛在出售事項所得款項可進一步加強集團的現金流量,從而令集團可就未來發展重新配置資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.